t
On 18 November 2026, Genus plc published an AGM trading update for the four months ended 31 October 2026. The company expects its FY27 constant-currency adjusted profit before tax to be in line with analyst expectations of £91.0m to £94.5m, alongside an expected £3m to £4m adverse currency impact for the year. Genus will announce its interim results for the six months ending 31 December 2026 on 25 February 2027.
| Date | 18 Nov 2026 |
| Time | 07:00:03 |
| Category | AGMs and other meetings |
| ID | 5778D |
18 November 2026
Genus plc (“Genus” or the “Group”)
AGM Trading Update – Solid start to the year
Genus (LSE: GNS), a leading global animal genetics company, publishes the following unaudited trading update for the four months ended 31 October 2026 to coincide with its AGM at 11:00am GMT today.
Genus has made a solid start to the year against a backdrop of softer global agricultural markets. Group FY27 adjusted profit before tax in constant currency is expected to be in line with current market expectations1 and second half weighted, as previously guided. Depreciation of the Brazilian real and Mexican peso against sterling during the period is now expected to result in a £3m to £4m adverse currency impact for the year, assuming current exchange rates persist.
PIC has delivered resilient trading despite challenging end-markets for its customers, reflecting the strength of its royalty-based business model, strong product performance and long-standing customer relationships.
ABS trading has been challenging as low global dairy prices continue to weigh on customer profitability. Management expects a material improvement in the second half supported by commercial and operational initiatives.
Genus will announce its interim results for the six months ending 31 December 2026 on 25 February 2027.
For further information please contact:
|
Genus plc |
Tel: +44 1256 345 970 |
|
Jorgen Kokke, Chief Executive Officer |
|
|
Andy Russell, Chief Financial Officer |
|
|
Anand Date, Investor Relations & Sustainability Director |
|
|
Tavistock Communications |
Tel: +44 2074 665 000 |
|
Nick Dibden |
|
|
Katie Hopkins |
|
|
Saskia Zilkha |
|
About Genus
Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRRS Resistant Pig is a market leading innovation in gene editing, which Genus is looking to commercialise in the porcine industry once regulatory approval is gained.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Footnotes
1 The Company compiled consensus estimate range for Group FY27 actual currency adjusted profit before tax is £91.0m to £94.5m with an average midpoint of £93.3m, and is based upon 13 analyst estimates